ArticleImmunologic research2025
Prevalence, incidence, and mortality of autoimmune diseases among adolescents and young adults in Mexico: an analysis based on the global burden of disease study 2021.
Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oxidative-Stress-Associated Molecular Signatures in Immune-Mediated Diseases: A Systematic Review Integrating Machine Learning and Systems Biology Approaches.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This nationwide analysis quantified the contemporary and future burden of six autoimmune diseases (ADs)-rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), asthma, and psoriasis-among Mexican adolescents and young adults (AYAs, 10-24 years) using the Global Burden of Disease 2021 database. Age-standardised prevalence (ASPR), incidence (ASIR), and mortality (ASMR) rates for 2021 were calculated by direct standardisation to the GBD world population; 1990-2021 temporal patterns were explored through Joinpoint regression to derive average annual percentage change, and Box-Jenkins ARIMA models projected trends up to 2035, incorporating diagnostic-capacity covariates. In 2021, RA had the greatest burden (ASPR 45.7/100,000; ASIR 9.1), with a striking female predominance and north-south variability. Although IBD remained infrequent, its mortality rose in states where colonoscopy access expanded, suggesting detection bias yet underscoring rising severity. MS prevalence and incidence climbed steadily, particularly among young women in urbanised regions. T1DM maintained the highest absolute caseload and incidence but showed slowly declining rates; nevertheless, ASMR inched upward, reflecting suboptimal metabolic control. Asthma, while still the most prevalent AD, exhibited a modest downward trajectory, whereas psoriasis incidence was stable, yet prevalence remained substantial, signalling chronic disease accumulation. Forecasts predict moderate growth in RA and MS cases, relative plateauing of IBD, asthma, and psoriasis, and continued contraction of T1DM incidence with a slight mortality uptick. Persistent geographic and sex-related inequities highlight the necessity for region-specific prevention strategies, earlier immune-modulating therapy, and equitable access to specialised care to mitigate the projected AD burden in Mexican AYAs.
Indexed as
Identifiers
41276722What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.